Esperion Therapeutics (ESPR) Q4 2024 earnings summary

Executive summary

• FY24 total revenue rose 186% year-over-year to $332.3M; Q4 revenue up 114% to $69.1M, driven by increased prescription demand, expanded US labels, and global market growth.

• U.S. net product revenue grew 48% in FY24 to $115.7M; Q4 U.S. net product revenue up 52% to $31.6M, with expanded payer access and prescriber base.

• Strategic partnerships, international launches, and new commercialization agreements in Australia, New Zealand, and Israel contributed to significant growth in patient access and revenue.

• Advanced pipeline with triple combination bempedoic acid therapies and ongoing R&D milestones support long-term innovation and cardiovascular benefits.

• Products now approved in 39 countries, with >25,000 prescribers and >173M lives covered globally.

Financial highlights

• Q4 2024 total revenue reached $69.1M, up 114% year-over-year; full year 2024 revenue was $332.3M, up 186% year-over-year.

• Collaboration revenue for Q4 was $37.6M (+227% YoY); full year collaboration revenue was $216.6M (+470% YoY), including a one-time milestone from Otsuka.

• Royalty revenue from Europe grew 9% sequentially to $9.7M in Q4 and 116% year-over-year to $32.6M for 2024.

• Cash and cash equivalents stood at $144.8M at year-end 2024, up from $82.2M a year earlier.

• Net loss narrowed to $51.7M for FY24 from $209.2M in FY23; operating income for FY24 was $54.4M, compared to a loss of $155.6M in FY23.

Outlook and guidance

• FY25 operating expenses expected between $215M and $235M, including ~$15M in non-cash stock compensation.

• Anticipates further revenue growth and operating profitability through US, European, and Japanese market expansion.

• Expects Health Canada approval for NEXLETOL and NEXLIZET in Q4 2025; Japan approval and pricing in H2 2025.

• Medicare coverage gap removal in 2025 expected to normalize gross-to-net rates and align revenue growth with prescription growth.

• Anticipates a stronger cash position by end of 2025, supported by global milestones.